Differential expression of Fas system apoptotic molecules in peripheral lymphocytes from patients with Graves' disease and Hashimoto's thyroiditis

European Journal of Endocrinology

Volumn 158, Issue 6, 2008, Pages 853-859

  Fountoulakis, Stelios ^a   Vartholomatos, George ^b   Kolaitis, Nikolaos ^b   Frillingos, Stathis ^a   Philippou, George ^a   Tsatsoulis, Agathocles ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND; THYROID ANTIBODY; THYROID HORMONE;

ADOLESCENT; ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; AUTOIMMUNE THYROIDITIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GRAVES DISEASE; HASHIMOTO DISEASE; HORMONE BLOOD LEVEL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; MAJOR CLINICAL STUDY; MALE; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; BLOOD; CHILD; LYMPHOCYTE; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD95; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; FEMALE; FLOW CYTOMETRY; GRAVES DISEASE; HASHIMOTO DISEASE; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED;

EID: 44949229246     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-08-0092     Document Type: Article

References (35)

1. Phelps E, Wu P, Bretz J & Baker JR Jr. Thyroid Cell apoptosis. A new understanding of thyroid autoimmunity. Endocrinology and Metabolism Clinics of North America 2000 29 375-388.
2. Weetman AP Autoimmune thyroid disease: propagation and progression. European Journal of Endocrinology 2003 148 1-9.
3. Fountoulakis S & Tsatsoulis A. On the pathogenesis of autoimmune thyroid disease: a unifying hypothesis. Clinical Endocrinology 2004 60 397-409.
4. Stassi G, Di Liberto D, Todaro M, Zeuner A, Ricci-Vitiani L, Stoppacciara A, Ruco L, Farina F, Zummo G & De Maria R. Control of target cell survival in thyroid autoimmunity by T helper cytokines via regulation of apoptotic proteins. Nature Immunology 2000 1 483-488.
5. Wang SH, Bretz JD, Phelps E, Mezosi E, Arscott PL, Utsugi S & Baker JR Jr. A unique combination of inflammatory cytokines enhances apoptosis of thyroid follicular cells and transforms nondestructive to destructive thyroiditis in experimental autoimmune thyroiditis. Journal of Immunology 2002 168 2470-2474.
6. Mitsiades N, Poulaki V, Mitsiades CS, Koutras DA & Chrousos GP. Apoptosis induced by FasL and TRAIL/Apo2L in the pathogenesis of thyroid diseases. Trends in Endocrinology and Metabolism 2001 12 384-390.
7. Arscott PL, Knapp J, Rymaszewski M, Bartron JL, Bretz JD, Thompson NW & Baker JR Jr. Fas (APO-1, CD95)-mediated apoptosis in thyroid cells is regulated by a labile protein inhibitor. Endocrinology 1997 138 5019-5027.
8. Wei Y, Chen K, Sharp GC & Braley-Mullen H. FLIP and FasL expression by inflammatory cells vs thyrocytes can be predictive of chronic inflammation or resolution of autoimmune thyroiditis. Clinical Immunology 2003 108 221-233.
9. Stassi G, Zeuner A, Di Liberto D, Todaro M, Ricci-Vitiani L & De Maria R. Fas-FasL in Hashimoto's thyroiditis. Journal of Clinical Immunology 2001 21 19-23.
10. Salmaso C, Bagnasco M, Pesce G, Montagna P, Brizzolara R, Altrinetti V, Richiusa P, Galluzzo A & Giordano C. Regulation of apoptosis in endocrine autoimmunity: insights from Hashimoto's thyroiditis and Graves' disease. Annals of the New York Academy of Sciences 2002 966 496-501.
11. Chen S, Fazle Akbar SM, Zhen Z, Luo Y, Deng L, Huang H & Li W. Analysis of the expression of Fas, FasL and Bcl-2 in the pathogenesis of autoimmune thyroid disorders. Cellular and Molecular Immunology 2004 1 224-228.
12. Borgerson KL, Bretz JD & Baker JR Jr. The role of Fas-mediated apoptosis in thyroid autoimmune disease. Autoimmunity 1999 30 251-264.
13. Andrikoula M & Tsatsoulis A. The role of Fas-mediated apoptosis in thyroid disease. European Journal of Endocrinology 2001 144 561-568.
14. Hammond LJ, Lowdell MW, Cerrano PC, Goode AW, Bottazzo GF & Mirakian R. Analysis of apoptosis in relation to tissue destruction associated with Hashimoto's autoimmune thyroiditis. Journal of Pathology 1997 182 138-144.
15. Hiromatsu Y, Hoshino T, Yagita H, Koga M, Sakisaka S, Honda J, Yang D, Kayagaki N, Okumura K & Nonaka K. Functional Fas ligand expression in thyrocytes from patients with Graves' disease. Journal of Clinical Endocrinology and Metabolism 1999 84 2896-2902.
16. Hammond LJ, Palazzo FF, Shattock M, Goode AW & Mirakian R. Thyrocyte targets and effectors of autoimmunity: a role for death receptors? Thyroid 2001 11 919-927.
17. Suda T, Hashimoto H, Tanaka T, Ochi T & Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. Journal of Experimental Medicine 1997 186 2045-2050.
18. Nagata S & Golstein P. The Fas death factor. Science 1995 267 1449-1456.
19. Van Parijs L, Biukians A & Abbas AK. Functional roles of Fas and Bcl-2-regulated apoptosis of T lymphocytes. Journal of Immunology 1998 160 2065-2069.
20. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ & Mountz JD. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994 263 1759-1762.
21. Hara H, Morita Y, Sato R & Ban Y. Circulating nuclear matrix protein in Graves' disease. Endocrine Journal 2002 49 343-347.
22. Ohtsuka K & Hashimoto M. Serum levels of soluble Fas in patients with Graves' ophthalmopathy. British Journal of Ophthalmology 2000 84 103-106.
23. Hiromatsu Y, Bednarczuk I Soyejima E, Miyake I, Yang D, Fukazawa H & Nonaka K. Increased serum soluble Fas in patients with Graves'disease. Thyroid 1999 9 341-345.
24. Feldkamp J, Pascher E, Schott M, Goretzki P, Seissler J & Scherbaum WA. Soluble Fas is increased in hyperthyroidism. independent of the underlying thyroid disease. Journal of Clinical Endocrinology and Metabolism 2001 86 4250-4253.
25. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K & Yagita H. Metalloproteinase-mediated release of human Fas ligand. Journal of Experimental Medicine 1995 182 1777-1783.
26. Tanaka M, Itai K, Adachi M & Nagata S. Downregulation of Fas ligand by shedding. Nature Medicine 1998 4 31-36.
27. Kandror VI, Babkina IV, Krainova SI, Kavtaradze SR & Kushlinskii NE. Increase in serum concentration of FAS ligand as a possible mechanism for antithyroid cytotoxicity during autoinumme thyroid diseases. Bulletin of Experimental Biology and Medicine 2004 138 37-39.
28. Mezosi E, Wang SH, Utsugi S, Bajnok L, Bretz JD, Gauger PG, Thompson NW & Baker JR Jr. Induction and regulation of Fas mediated apoptosis in human thyroid epithelial cells. Molecular Endocrinology 2005 19 804-811.
29. Kawakami A, Matsuoka N, Tsuboi M, Koji T, Urayama S, Sera N, Hida A, Usa T, Kimura H, Yokoyama N, Nakashima T, Ishikawa N, Ito K, Kawabe Y & Eguchi K. CD4+T cell-mediated cytotoxicity toward thyrocytes: the importance of Fas/Fas ligand interaction inducing apoptosis of thyrocytes and the inhibitory effect of thyroid-stimulating hormone. Laboratory Investigation 2000 80 471-484.
30. Giordano C, Richiusa P, Bagnasco M, Pizzolanti G, Di Blasi F, Sbriglia MS, Mattina A, Pesce G, Montagna P, Capone F, Misiano G, Scorsone A, Pugliese A & Galluzzo A. Differential regulation of Fas-mediated apoptosis in both thyrocyte and lymphocyte cellular compartments correlates with opposite phenotypic manifestations of autoimmune thyroid disease. Thyroid 2001 11 233-244.
31. Mitsiades N, Poulaki V, Tseleni-Balafouta S, Chrousos GP & Koutras DA. Fas ligand expression in thyroid follicular cells from patients with thionamide treated Graves' disease. Thyroid 2000 10 527-532.
32. Maruoka H, Watanabe M, Matsuzuka F, Takimoto T, Miyauchi A & Iwatami Y. Increased intensities of Fas expression on peripheral T cell subsets in severe autoimmune thyroid disease. Thyroid 2004 14 417-423.
33. Shimaoka Y, Hidaka Y, Okumura M, Takeoka K, Tada H & Amino N. Serum concentration of soluble Pas in patients with autoimmune thyroid diseases. Thyroid 1998 8 43-47.
34. Takeda K, Ohara E, Kaneda T, Hashimoto K & Sasaki M. Increased serum soluble Fas ligand in hyperthyroid Graves' disease. Rinsho Byori 1999 47 961-965.
35. Nakamura Y, Watanabe M, Matsuzuka F, Maruoka H, Miyauchi A & Iwatani Y. Intrathyroidal CD4+T lymphocytes express high levels of Fas and CD4+CD8+ Macrophage/dendritic cells express Fas Ligand in autoimmune thyroid disease. Thyroid 2004 14 819-824.